Abstract
A silk fibroin hydrolysate (SFH) exhibited a pronounced in vivo blood pressure-lowering effect on spontaneously hypertensive rats (SHRs) accompanied with decreases in the plasma angiotensin II, endothelin (ET), TNF-α and NO concentrations. We also observed a markedly decreased LPO level, a parameter of oxidative tissue damage, in the medium- and high-dose SFH-treated groups which was accompanied by an increased SOD level in erythrocytes. Our data suggest ACE inhibition together with an improved antioxidative status as the underlying antihypertensive mechanism for the silk fibroin hydrolysate. Since SFH could markedly lower the blood pressure and improve several physiological parameters involved in the occurrence of hypertension, it could be used as a possible supplement against cardiovascular diseases and as a functional food ingredient.
